FTC Order Blocks Fresenius’ Ability To Inflate Medicare Venofer
The Federal Trade Commission is offering to set aside concerns with a Venofer licensing deal between Fresenius and Daiichi Sankyo if Fresenius continues to report a product price to Medicare that is no higher than the current market price
You may also be interested in...
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.